Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy
AUTOR(ES)
Friedman, Lilach M.
FONTE
National Academy of Sciences
RESUMO
mAbs to receptor tyrosine kinases such as EGF receptor/ErbB-1 and HER2/ErbB-2 inhibit the tumorigenic growth of certain cancer cells, but although recombinant versions of such Abs are already used in oncology wards, the mechanism underlying immunotherapy remains unknown. We report that anti-EGF receptor Abs promote a slow endocytic process distinct from the rapid EGF-induced receptor internalization. Combining mAbs that engage distinct epitopes significantly accelerates receptor degradation. In addition, mAb combinations are more effective than single Abs in inhibiting HER2 signaling in vitro and tumorigenesis in animals. We present a model attributing efficacy of immunotherapy to the size of Ab-receptor lattices formed at the cell surface, which dictates the rate of endocytic clearance and extent of signaling blockade.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=548578Documentos Relacionados
- Down-regulation of cellular platelet-derived growth factor receptors induced by an activated neu receptor tyrosine kinase.
- Picornavirus Receptor Down-Regulation by Plasminogen Activator Inhibitor Type 2
- Mechanism for down-regulation of CD28 by Nef
- Insulin receptor activation and down-regulation by cationic lipid transfection reagents
- Down-regulation of beta-adrenergic receptors: agonist-induced reduction in receptor mRNA levels.
